Work

Dichloroacetate nanoparticles and doxorubicin combinatorial treatment augment the hepato-renal function in Ehrlich ascites carcinoma cells

Year: 2025

Type: article

Abstract: OBJECTIVES: Cancer cells are addressed through conventional chemotherapy, resulting in tumour resistance and systemic toxicities affecting organ functions. Nanoparticle (NPs) represent a promising approach to improve chemotherapeutic efficacy and reduce adverse effects. This study aims to improve hepato-renal function by dichloroacetate nanoparticles (DCA-PNPs) and doxorubicin (Dox) combinatorial treatment in Ehrlich ascites carcinoma (EAC) model. RESULTS: Dichloroacetate nanoparticles characterizations showed effective drug encapsulation, optimal particles size, morphology, and distribution. Biochemical analysis showed normalized protein content, improved lipid profile, enhanced liver, kidney functions, antioxidant activity, and decreased oxidative-stress with Dox/DCA-PNPs combination treatment, indicating that NPs-based therapy enhanced therapeutic outcomes and minimized systemic toxicity via mitigated Dox side effects and maintained organ's function. This study elucidates that Dox/DCA-PNPs combination therapy provides a more effective strategy for EAC hepatorenal function improvements.

Source: BMC Research Notes

DOI: 10.1186/s13104-025-07534-3

Authors: Amira T. Khattab, Mai M. El-Keiy, Doha M. Beltagy, Maha M. Salem

Institutions: Damanhour University, Tanta University

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,690